Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited is intensifying its presence in the photomedicine sector, announcing the expansion of its commercial operations, including the distribution of SCENESSE® across the US and the EU. The company is targeting to train and accredit 120 US centers by 2025 to treat vitiligo, with the aim of becoming the industry leader in photodermatology. Clinuvel has already seen promising results in vitiligo treatment with SCENESSE® combined with phototherapy, which is expected to streamline patient care and offer a more efficient treatment cycle.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
